Yuhan Corporation and Oscotec Win Best Pharmaceutical Product at Inaugural Prix Galien Korea for Lazertinib
Yuhan and Oscotec were jointly awarded the “Best Pharmaceutical Product” for lazertinib (LECLAZA®/LAZCLUZE™) at the inaugural Prix Galien Korea Awards, held on September 10, 2026, at The Shilla Seoul. Established in France in 1970, the Prix Galien recognizes innovations in pharmaceuticals, biotechnology, medical technology, and other areas of healthcare. This year’s ceremony marked the first Prix Galien held in Korea and […]
BlackRock Increases Stake in Yuhan for Second Consecutive Month
BlackRock, the world’s largest asset manager, has increased its equity stake in Yuhan for the second consecutive month. According to the industry, BlackRock Fund Advisors, which manages BlackRock’s funds, and its special affiliates bought 745,717 shares of Yuhan on the market through the 31st of last month. As a result, BlackRock’s Yuhan holdings increased from […]
Yuhan gets USD 30 Million from J&J as Lazcluze-Rybrevant reaches Europe
Yuhan Corporation announced that it will receive a $30 million milestone payment from Johnson & Johnson following the European commercial launch of lazertinib (Korean brand name: Leclaza) for the treatment of non-small cell lung cancer (NSCLC). The milestone was triggered by the European market entry of the combination therapy of lazertinib and amivantamab. Including this […]
Yuhan Secures USD 45 Million Milestone Payment for Lecraza’s Entry into the Chinese Market
Yuhan Corporation announced that it will receive a milestone payment of USD 45 million (approximately KRW 69 billion) from Janssen Biotech following the commercial launch of Lazertinib (brand name Lecraza) in China. The payment was triggered by the achievement of a development milestone related to the combination therapy of Lazertinib and Janssen’s Amivantamab (brand name […]
NEJM Publishes Phase 3 MARIPOSA Trial: Amivantamab plus Lazertinib Sets New Standard in EGFR-Mutant NSCLC
Through global collaboration with multinational pharmaceutical companies, a domestically developed anticancer drug has once again been published in the world-renowned New England Journal of Medicine (NEJM). On September 7, the final analysis of the phase 3 MARIPOSA trial in non-small cell lung cancer (NSCLC), with Professor Byoung Chul Cho of Yonsei University College of Medicine […]
Yuhan Signs HIV Drug API Supply Contract with Gilead
On the 20th, Yuhan Corporation announced that it has signed a contract with multinational pharmaceutical company Gilead Sciences to supply the active pharmaceutical ingredient (API) for HIV treatments. The contract is valued at approximately USD 60.7 million (KRW 84.27 billion), representing 4.08% of Yuhan’s total sales last year, and covers the period from March 31, […]
Lazertinib + SBRT Shows Promising Results in EGFR-Mutant Oligometastatic NSCLC
A phase 2 clinical trial led by Korean investigators demonstrated that combining the third-generation EGFR inhibitor lazertinib (Leclaza® in Korea, Lazcluzy® internationally) with stereotactic body radiotherapy (SBRT) significantly prolonged progression-free survival (PFS) compared with lazertinib alone in patients with EGFR-mutant oligometastatic non-small cell lung cancer (NSCLC). The multicenter, randomized study enrolled 67 patients with EGFR […]
Amivantamab + Lazertinib Shows Significant Benefits in EGFR-Mutant NSCLC
Johnson & Johnson’s Innovative Medicine (formerly Janssen) reported that the combination of amivantamab (Rybrevant®) and lazertinib (Leclaza® in Korea, Lazcluze® internationally), developed by Yuhan Corporation, provides a survival benefit of over one year compared with osimertinib (Tagrisso®) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The combination also significantly reduced EGFR- and MET-related resistance, […]
Janssen Gains China Approval for Lazertinib + Amivantamab Combo in EGFR-Mutant NSCLC
Date: 08/01/25 Yuhan Corporation’s novel EGFR-targeting non-small cell lung cancer (NSCLC) therapy Leclaza (lazertinib) has received official marketing approval in China, further solidifying its global footprint. The Chinese National Medical Products Administration (NMPA) approved the combination therapy of Leclaza and Rybrevant (amivantamab), expanding the drug’s availability to the world’s three largest pharmaceutical markets: the U.S., […]
Yuhan Presents Phase 1b Part 2 Results for Lesigercept – Shows Efficacy in Omalizumab-Refractory Patients
Date: 6/13/25 Yuhan Corporation presented positive Phase 1b Part 2 results for its investigational anti-IgE biologic Lesigercept (YH35324) at the EAACI 2025 Annual Meeting in Glasgow. Lesigercept is a novel Fc-fusion protein that binds to both circulating free IgE and FcεRIα autoantibodies, offering a dual mechanism to alleviate allergic symptoms. The study focused on 9 […]